{"corpus_id":6888582,"paper_sha":"2f793f2c4d8c9c506aca54fdb8e214140d6b0a52","doi":"10.4103/2008-322X.180706","arxiv_id":null,"pmid":27195088,"pmcid":"4860990","mag_id":2338016719,"dblp_id":null,"acl_id":null,"title":"Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy","year":2016,"publication_date":null,"venue":"Journal of Ophthalmic & Vision Research","journal":{"name":"Journal of Ophthalmic & Vision Research","pages":"66 - 69","volume":"11"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","Review"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":20,"citation_count":14,"influential_citation_count":0,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Purpose: To report the outcomes of half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC). Methods: A chart review of patients with chronic CSC who had received half-dose verteporfin PDT (3 mg/m2) was performed. The main outcome measures were resolution of subretinal fluid and best corrected visual acuity (BCVA). Results: Fifty-three eyes of 51 patients with mean age of 45.01 ± 8.9 years were studied. Three, 6 and 12 months after half-dose PDT, subretinal fluid was completely resolved in 51 eyes (96.2%). In 2 eyes (one patient), subretinal fluid decreased at 3 months but one year later, an increase in subretinal fluid was detected on optical coherence tomography (OCT) which completely resolved following additional PDT. Another patient with recurrence of subretinal fluid rejected further treatment. Mean baseline central subfield thickness was 385 ± 113.0 μm which was decreased to 235 ± 39.7, 247 ± 49.7, and 244 ± 49.52 μm after 3, 6 and 12 months, respectively (all P-values < 0.001). Mean BCVA was 0.33 ± 0.27 LogMAR before PDT and 0.11 ± 0.18, 0.11 ± 0.17, 0.17 ± 0.26 and 0.10 ± 0.23 LogMAR, 3, 6 and 12 months and at final visit (up to 60 months) after PDT, respectively (all P-values < 0.001). Improvement ≥2 lines in BCVA occurred in 20 eyes (37.7%). Statistically significant correlations were found between improvement in BCVA and baseline BCVA, baseline central subfield thickness and central subfield thickness after resorption of subretinal fluid (P < 0.001, P= 0.04 and P= 0.01, respectively). No complications attributed to PDT were observed. Conclusion: Half-dose PDT is effective for treatment of patients with chronic CSC.","claims":[{"public_id":"cl_258ea97195c451887f00a8fe34cfea8c","status":"active","text":"An improvement of at least two lines in best corrected visual acuity occurred in 37.7% of eyes, and improvement in visual acuity correlated with baseline visual acuity, baseline central subfield thickness, and central subfield thickness after resorption of subretinal fluid.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_258ea97195c451887f00a8fe34cfea8c"},{"public_id":"cl_53fc68de81b9cd344d22bc7f873b2b2c","status":"active","text":"Best corrected visual acuity improved significantly after photodynamic therapy, with mean LogMAR decreasing from 0.33 ± 0.27 at baseline to 0.11 ± 0.18 at 3 months, 0.11 ± 0.17 at 6 months, 0.17 ± 0.26 at 12 months, and 0.10 ± 0.23 at the final visit.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_53fc68de81b9cd344d22bc7f873b2b2c"},{"public_id":"cl_96cd2dd02b09c09744bbe619ab11fa6f","status":"active","text":"Central subfield thickness decreased significantly from 385 ± 113.0 μm at baseline to 235 ± 39.7, 247 ± 49.7, and 244 ± 49.52 μm at 3, 6, and 12 months, respectively.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_96cd2dd02b09c09744bbe619ab11fa6f"},{"public_id":"cl_3b73a01fef0af35b1f5b1b01d367ac4d","status":"active","text":"Half-dose verteporfin photodynamic therapy produced complete resolution of subretinal fluid in 96.2% of treated eyes by 3, 6, and 12 months.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_3b73a01fef0af35b1f5b1b01d367ac4d"},{"public_id":"cl_1dbf08918aead330da69bb96dd1dd1e8","status":"active","text":"No complications attributed to photodynamic therapy were observed.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_1dbf08918aead330da69bb96dd1dd1e8"}],"concepts":[{"public_id":"co_1327be64d627714ce4748470418a9581","status":"active","name":"chronic central serous chorioretinopathy","description":"A chronic retinal disorder characterized by persistent serous detachment and subretinal fluid.","types":["condition"],"aliases":["chronic CSC","CSC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1327be64d627714ce4748470418a9581"},{"public_id":"co_282da201852b7e96aa8f2834af433877","status":"active","name":"LogMAR","description":"A logarithmic scale used to quantify visual acuity.","types":["measurement scale"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_282da201852b7e96aa8f2834af433877"},{"public_id":"co_5eb3394dcb06e17a2851d9cfff740232","status":"active","name":"subretinal fluid","description":"Fluid accumulation beneath the neurosensory retina used as a key treatment outcome.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5eb3394dcb06e17a2851d9cfff740232"},{"public_id":"co_6ba38885d3edc15a36a46027e8418221","status":"active","name":"best corrected visual acuity","description":"The best vision a patient can achieve with optimal refractive correction, measured here in LogMAR.","types":["outcome","measurement"],"aliases":["BCVA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6ba38885d3edc15a36a46027e8418221"},{"public_id":"co_9c4cde4692dc3983ddd1fb9cd2b7add5","status":"active","name":"half-dose verteporfin photodynamic therapy","description":"A photodynamic therapy regimen using a reduced 3 mg/m2 dose of verteporfin.","types":["treatment","method"],"aliases":["half-dose PDT","half-dose photodynamic therapy","PDT","verteporfin PDT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9c4cde4692dc3983ddd1fb9cd2b7add5"},{"public_id":"co_a21d4a4446c0ca1bf8b6c37019d14582","status":"active","name":"optical coherence tomography","description":"An imaging technique used to assess retinal structure and fluid status.","types":["imaging technique","measurement technique"],"aliases":["OCT"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a21d4a4446c0ca1bf8b6c37019d14582"},{"public_id":"co_b26861aab38ff189a728dbd9f1e952d4","status":"active","name":"central subfield thickness","description":"The thickness of the central retinal subfield measured on ocular imaging.","types":["measurement","outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b26861aab38ff189a728dbd9f1e952d4"},{"public_id":"co_dc7a1d19367411be70ca286d0f535abe","status":"active","name":"complications","description":"Adverse events or treatment-related harms observed during follow-up.","types":["outcome","safety"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_dc7a1d19367411be70ca286d0f535abe"}],"external_ids":{"DOI":"10.4103/2008-322X.180706","ArXiv":null,"PubMed":27195088,"PubMedCentral":"4860990","MAG":2338016719,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/6888582","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632862,"paper_uid":"97f9a4ad-7060-4110-9932-3271135afd4d","canonical_identity":{"paper_id":632862,"paper_uid":"97f9a4ad-7060-4110-9932-3271135afd4d","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/6888582"}